Sakae Asanuma
Chief Executive Officer chez Taiho Ventures LLC
Profil
Sakae Asanuma established Taiho Ventures as the founding President in 2016.
Prior to joining Taiho, he was President and CEO at Astellas Venture Management and US Head of Astellas Innovation Management in 2011-2015.
Prior to Astellas, he worked for Yasuda Enterprise, a Japan/US-based VC firm in 2000-2011.
He has invested in more than 50 biotech companies since 2000 and majority of his portfolios achieved IPOs or M&AS.
During his tenure at Taiho and Astellas, he led to executed dozens of research collaboration deals with academia and biotech ventures, including several build-to-buys or spin-outs.
Postes actifs de Sakae Asanuma
| Sociétés | Poste | Début |
|---|---|---|
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Director/Board Member | - |
Axial Therapeutics, Inc.
 Axial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA. | Director/Board Member | - |
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a private company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million. | Director/Board Member | - |
Taiho Ventures LLC
 Taiho Ventures LLC Investment ManagersFinance Taiho Ventures LLC (Taiho Ventures) is a venture and private equity subsidiary of Taiho Pharmaceutical Co Ltd founded in 2016. The firm is headquartered in Menlo Park, California. | Chief Executive Officer | 01/04/2016 |
Anciens postes connus de Sakae Asanuma
| Sociétés | Poste | Fin |
|---|---|---|
| WEREWOLF THERAPEUTICS, INC. | Director/Board Member | 15/04/2022 |
Astellas Venture Management LLC
 Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Phrama Inc founded in 2000. The firm is headquartered in Brisbane, California. | Chief Executive Officer | 31/01/2016 |
| Yasuda Enterprise Development America, Inc. | Corporate Officer/Principal | - |
Meiji Yasuda Life Insurance Co.
 Meiji Yasuda Life Insurance Co. Life/Health InsuranceFinance Meiji Yasuda Life Insurance Co. is engaged in the provision of life insurance services. Its business activities include individual insurance marketing, general agent marketing, group insurance marketing, underwriting, policyholder services, claim payments, asset management and international insurance services. The company was founded on July 9, 1881 and is headquartered in Tokyo, Japan. | Corporate Officer/Principal | 01/01/1999 |
| ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Sakae Asanuma
| Carnegie Mellon University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| WEREWOLF THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Meiji Yasuda Life Insurance Co.
Meiji Yasuda Life Insurance Co. Life/Health InsuranceFinance Meiji Yasuda Life Insurance Co. is engaged in the provision of life insurance services. Its business activities include individual insurance marketing, general agent marketing, group insurance marketing, underwriting, policyholder services, claim payments, asset management and international insurance services. The company was founded on July 9, 1881 and is headquartered in Tokyo, Japan. | Finance |
Astellas Venture Management LLC
Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Phrama Inc founded in 2000. The firm is headquartered in Brisbane, California. | Finance |
| Yasuda Enterprise Development America, Inc. | |
Mitobridge, Inc.
 Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA. | Health Technology |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Health Technology |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Taiho Ventures LLC
Taiho Ventures LLC Investment ManagersFinance Taiho Ventures LLC (Taiho Ventures) is a venture and private equity subsidiary of Taiho Pharmaceutical Co Ltd founded in 2016. The firm is headquartered in Menlo Park, California. | Finance |
Axial Therapeutics, Inc.
Axial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA. | Health Technology |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a private company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million. | Health Technology |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Health Technology |
